Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

Induction of CXCL1 in Osteoblasts by Myeloma Cells Promotes Migration of Osteoclast Precursors

Martin F. Kaiser, MD, Ulrike Heider, MD, Maren Mieth, PhD, Jozef Zustin, MD, Andrea Kuehnl, MD, Ivana von Metzler, MD, Orhan Sezer, MD, PhD

Blood (2012) 120 (21): 441.

https://doi.org/10.1182/blood.V120.21.441.441

Published: 2012

Journal Articles

The Proteasome Inhibitor Bortezomib Stimulates Osteoblastic Differentiation of Human Osteoblast Precursor Cells Via Upregulation of Vitamin D Receptor Signaling

Martin Kaiser, Maren Mieth, Orhan Sezer, MD, PhD, Ulrike Heider

Blood (2010) 116 (21): 1899.

https://doi.org/10.1182/blood.V116.21.1899.1899

Published: 2010

Journal Articles

An Angiogenic Risk Score Improves the Prognostic Information of the International Staging System in Patients with Symptomatic Multiple Myeloma.

Christian Jakob, MD,, Theresa Wernecke, MD, Jan Sterz, MD, Andrea Goerke, MD, Ulrike Heider, MD, Martin Kaiser, MD, Maren Mieth, PhD, Susanne Ziefle, MD, Orhan Sezer, MD, PhD

Blood (2009) 114 (22): 2802.

https://doi.org/10.1182/blood.V114.22.2802.2802

Published: 2009

Journal Articles

Synergistic Interaction of the Heat Shock Protein 90 Inhibitor NVP-AUY922 and the Histone Deacetylase Inhibitor NVP-LBH589 in Multiple Myeloma

Martin Kaiser, Britta Lamottke, Michael R. Jensen, Cornelia Quadt, Carlos Garcia-Echeverria, Maren Mieth, Ulrike Heider, Orhan Sezer

Blood (2008) 112 (11): 5164.

https://doi.org/10.1182/blood.V112.11.5164.5164

Published: 2008

Journal Articles

Serum Concentrations of DKK-1 Correlate with the Extent of Bone Disease in Multiple Myeloma.

Martin Kaiser, MD, Maren Mieth, PhD, Peter Liebisch, MD, PhD, Susanne Rötzer, Christian Jakob, MD, Claudia Fleissner, MD, Edgar Braendle, MD, PhD, David Stover, PhD, Malte Peters, MD, PhD, Orhan Sezer, MD, PhD, Ulrike Heider, MD

Blood (2007) 110 (11): 3518.

https://doi.org/10.1182/blood.V110.11.3518.3518

Published: 2007

Journal Articles

Bortezomib Inhibits Human Osteoclastogenesis.

Ivana Zavrski, MD, Monica Hecht, PhD, Holger Krebbel, Claudia Fleissner, MD, Maren Mieth, PhD, Martin Kaiser, MD, Ulrike Heider, MD, Christian Jakob, MD, Jan Sterz, Kurt Possinger, MD, Orhan Sezer, MD

Blood (2006) 108 (11): 1395.

https://doi.org/10.1182/blood.V108.11.1395.1395

Published: 2006

NARROW

Induction of CXCL1 in Osteoblasts by Myeloma Cells Promotes Migration of Osteoclast Precursors

The Proteasome Inhibitor Bortezomib Stimulates Osteoblastic Differentiation of Human Osteoblast Precursor Cells Via Upregulation of Vitamin D Receptor Signaling

An Angiogenic Risk Score Improves the Prognostic Information of the International Staging System in Patients with Symptomatic Multiple Myeloma.

Synergistic Interaction of the Heat Shock Protein 90 Inhibitor NVP-AUY922 and the Histone Deacetylase Inhibitor NVP-LBH589 in Multiple Myeloma

Serum Concentrations of DKK-1 Correlate with the Extent of Bone Disease in Multiple Myeloma.

Bortezomib Inhibits Human Osteoclastogenesis.

Email alerts

ASH Publications

American Society of Hematology

Induction of CXCL1 in Osteoblasts by Myeloma Cells Promotes Migration of Osteoclast Precursors

The Proteasome Inhibitor Bortezomib Stimulates Osteoblastic Differentiation of Human Osteoblast Precursor Cells Via Upregulation of Vitamin D Receptor Signaling

An Angiogenic Risk Score Improves the Prognostic Information of the International Staging System in Patients with Symptomatic Multiple Myeloma.

Synergistic Interaction of the Heat Shock Protein 90 Inhibitor NVP-AUY922 and the Histone Deacetylase Inhibitor NVP-LBH589 in Multiple Myeloma

Serum Concentrations of DKK-1 Correlate with the Extent of Bone Disease in Multiple Myeloma.

Bortezomib Inhibits Human Osteoclastogenesis.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only